HUTCHMED (China) (HMDCF) EBT Margin Growth (5y) (2020 - 2021)
Powered by 
Analysis
HUTCHMED (China) (HMDCF) EBT Margin Growth (5y) (2020 - 2021) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.93 Bn | 198.94 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.03 Bn | 177.85 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.73 Bn | 124.87 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.26 Bn | 74.27 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.30 Bn | 56.11 Bn | 1.37 Bn |
| 6 | Moderna | 54.88 Bn | 49.75 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.05 Bn | 30.74 Bn | 992.69 Mn |
| 8 | Biogen | 31.22 Bn | 29.94 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.91 Bn | 29.91 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |